- Trial phase
- Approved / Commercial
- Time to market
- Already approved and commercializing in the EU (since Nov 2025), China (since Jul 2026), and Brazil (since Sep 2026). No US filing planned.
- Why 3/10
- Kyinsu is already approved and commercializing in the EU, China, and Brazil. There is no pending PDUFA date or pivotal readout in the next 12 months. The most recent catalyst was the CHMP positive opinion for an indication change on October 15, 2026, but that is a label expansion for an already-marketed drug, not a binary event. As an approved product at a mega-cap company, the impact score is 3.
Kyinsu is already approved in the EU, China, and Brazil with no pending US filing. The next near-term event is the European Commission's formal decision on the CHMP-recommended indication change (positive opinion October 15, 2026), which is a routine label expansion, not a binary catalyst. Watch for commercial uptake data in Novo Nordisk's quarterly earnings and any potential US regulatory path if the insulin icodec issues are resolved.
Price Chart
Executive Summary
Kyinsu (IcoSema) is Novo Nordisk's once-weekly fixed-ratio injection combining insulin icodec and semaglutide for type 2 diabetes. It is the first product of its kind to pair a once-weekly basal insulin with a GLP-1 receptor agonist in a single shot. Kyinsu received EU marketing authorization in November 2025, launched in China in July 2026, and was approved in Brazil in September 2026. However, it has no US filing path after the FDA rejected the insulin icodec component (Awiqli) in 2024 over hypoglycemia concerns. The drug is now commercial-stage with no pending binary catalysts, and for a mega-cap company like Novo Nordisk, it represents a modest product among a large portfolio dominated by Ozempic/Wegovy.
How It Works
Kyinsu is a once-weekly injection that combines two diabetes drugs in one shot: insulin icodec (a long-acting insulin that helps the body absorb blood sugar) and semaglutide (a GLP-1 receptor agonist that stimulates the pancreas to release more insulin and reduces appetite). Together they control blood glucose in adults with type 2 diabetes who are not well controlled on their current treatment.
Trial Status
The Phase 3a COMBINE program (COMBINE 1-3) has been completed. COMBINE 3 (52-week, open-label) met its primary endpoint of non-inferior HbA1c reduction versus daily basal-bolus insulin therapy. COMBINE 2 compared IcoSema versus once-weekly semaglutide alone. The data supported global regulatory filings.
The Two-Sided Case
Upcoming Catalysts
- European Commission decision on CHMP-recommended indication label expansion (positive opinion adopted October 15, 2026)
- Quarterly commercial sales updates in Novo Nordisk earnings reports
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S 6-K NVO ·Originating report